Healthcare provider profile · identity verified

Sundee L Gable

Allopathic & Osteopathic Physicians|Internal Medicine · WILLOW GROVE, PA · NPI 1750386272

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sundee L Gable received $46.94 in general payments during 2025 across 2 reported records.

Exact Sciences Corporation accounted for 56.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$46.94

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Exact Sciences Corporation Unresolved — no canonical attribution shown $26.7256.9%12025
Lilly USA, LLC Unresolved — no canonical attribution shown $20.2243.1%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$46.942

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Cologuard Collection Kit
Normalized: cologuard collection kit
Device Exact Sciences Corporation $26.72 1 2025
Source payment records
MOUNJARO
Normalized: mounjaro
Drug Lilly USA, LLC $20.22 1 2025
Source payment records
ZEPBOUND
Normalized: zepbound
Drug Lilly USA, LLC $20.22 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium27078
Amlodipine BesylateAmlodipine Besylate26976
Levothyroxine SodiumLevothyroxine Sodium25768
Rosuvastatin CalciumRosuvastatin Calcium20062
Losartan PotassiumLosartan Potassium17948
LisinoprilLisinopril12231
SimvastatinSimvastatin12236
Escitalopram OxalateEscitalopram Oxalate11735
HydrochlorothiazideHydrochlorothiazide9531
Pantoprazole SodiumPantoprazole Sodium8827
Olmesartan MedoxomilOlmesartan Medoxomil8522
Metoprolol SuccinateMetoprolol Succinate8024
OmeprazoleOmeprazole7723
Metformin Hcl ErMetformin Hcl7019
LorazepamLorazepam6919
Fluticasone PropionateFluticasone Propionate6724
Bupropion XlBupropion Hcl6320
AlprazolamAlprazolam5817
Metformin HclMetformin Hcl5614
ClonazepamClonazepam5415
FamotidineFamotidine5417
Zolpidem TartrateZolpidem Tartrate5225
AtenololAtenolol5112
GabapentinGabapentin5023
AzithromycinAzithromycin4643
EliquisApixaban43suppressed
Sertraline HclSertraline Hcl4313
Venlafaxine Hcl ErVenlafaxine Hcl43suppressed
Citalopram HbrCitalopram Hydrobromide4111
MeloxicamMeloxicam3815
Albuterol Sulfate HfaAlbuterol Sulfate3623
HydrocortisoneHydrocortisone3528
OzempicSemaglutide34suppressed
SynthroidLevothyroxine Sodium3411
PrednisonePrednisone3329
FurosemideFurosemide3113
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide31suppressed
ValsartanValsartan31suppressed
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide31suppressed
IrbesartanIrbesartan29suppressed
Potassium ChloridePotassium Chloride28suppressed
Tamsulosin HclTamsulosin Hcl28suppressed
CelecoxibCelecoxib24suppressed
ClopidogrelClopidogrel Bisulfate24suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide24suppressed
NaproxenNaproxen2421
Metoprolol TartrateMetoprolol Tartrate23suppressed
CefuroximeCefuroxime Axetil2220
Duloxetine HclDuloxetine Hcl22suppressed
Paroxetine HclParoxetine Hcl22suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav2120
CephalexinCephalexin2118
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid21suppressed
MirtazapineMirtazapine20suppressed
Montelukast SodiumMontelukast Sodium20suppressed
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide20suppressed
Trazodone HclTrazodone Hcl20suppressed
ChlorthalidoneChlorthalidone19suppressed
EzetimibeEzetimibe19suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium18suppressed
Fluoxetine HclFluoxetine Hcl18suppressed
RepaglinideRepaglinide18suppressed
FinasterideFinasteride17suppressed
LevofloxacinLevofloxacin1717
Nifedipine ErNifedipine16suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst1616
PrimidonePrimidone16suppressed
Ciprofloxacin HclCiprofloxacin Hcl1514
NadololNadolol15suppressed
NystatinNystatin1513
RizatriptanRizatriptan Benzoate14suppressed
Serevent DiskusSalmeterol Xinafoate14suppressed
Tresiba Flextouch U-100Insulin Degludec14suppressed
DiazepamDiazepam13suppressed
Flecainide AcetateFlecainide Acetate13suppressed
Memantine Hcl ErMemantine Hcl13suppressed
Pravastatin SodiumPravastatin Sodium13suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim1311
ValacyclovirValacyclovir Hcl13suppressed
TemazepamTemazepam12suppressed
Warfarin SodiumWarfarin Sodium12suppressed
Amitriptyline HclAmitriptyline Hcl11suppressed
Azelastine HclAzelastine Hcl11suppressed
EtodolacEtodolac11suppressed
RisperidoneRisperidone11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $46.94 · 2 records Exact Sciences Corporation Cologuard Collection Kit, MOUNJARO, ZEPBOUND
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error